Drug Search Results
More Filters [+]

Elzasonan

Alternative Names: elzasonan
Latest Update: 2008-11-03
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 5-HT1B Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Elzasonan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Depressive Disorder, Major

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2005-004780-34

P2

Completed

Depressive Disorder, Major

2007-07-17

A7571001

P2

Completed

Depressive Disorder, Major

None

Recent News Events

Date

Type

Title